Lumida
/ALHC
⌘K
Alignment Healthcare Inc

Alignment Healthcare Inc

ALHC
$20.60USD↑+2.85%+0.57 today

MARKET CAP

4.3B

P/E (TTM)

222.6x

FWD P/E

64.0x

DAY RANGE

$20 – $21

52W RANGE

$12
$25

AI Summary

Stalk
StalkMedium

ALHC remains in a Stage 2 corrective advance but has stalled under its short EMAs, making current timing unfavorable for bullish engagement. The medium-term bias stays bullish, supported by higher lows and a rising 50-DMA, but price action under 9/21 EMAs warrants a deferred entry. Execution should stalk pullbacks into the rising 50-DMA and base support for potential acceptance. A decisive reclaim above the short EMAs with follow-through would validate the bullish posture, while a drop below the 50-DMA would invalidate.

  • ↑Membership grew 31% YoY to 284.8K; Q1 2026 revenue rose 33% to $1.2B.
  • ↑Q1 adjusted EBITDA reached $38M (3.1% margin), up 88% YoY; cash $726M.
  • ↓Securities fraud probe and whistleblower suit triggered a 16.7% share price drop.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Alignment Healthcare, Inc. (NASDAQ: ALHC) operates within the Medicare Advantage market, focusing on innovative solutions to enhance care delivery and outcomes for seniors. The company has been experiencing substantial growth, evidenced by a considerable uptick in health plan memberships and revenue, positioning itself favorably amidst a competitive landscape characterized by evolving regulatory frameworks. Their strategic emphasis on technology application and clinical management capabilities further sharpen their competitive edge, making them a significant player in the healthcare sector.

Bull says

  • ↑Membership grew 31% YoY to 284.8K; Q1 2026 revenue rose 33% to $1.2B.
  • ↑Q1 adjusted EBITDA reached $38M (3.1% margin), up 88% YoY; cash $726M.
  • ↑Strategic AI and automation investments aim to boost efficiency and scale.
  • ↑Market expansion planned for 2027 targeting high-acuity seniors to fuel growth.
  • ↑Fortune 1000 listing and positive analyst revisions enhance credibility and support.
  • ↑Management confident in model resilience; margins expected to improve further.

Bear says

  • ↓Securities fraud probe and whistleblower suit triggered a 16.7% share price drop.
  • ↓Negative earnings yield and weak profitability metrics heighten expense management concerns.
  • ↓High stock volatility and limited institutional backing suggest market skepticism.
  • ↓Focus on high-acuity populations may compress margins if costs outpace revenue.
  • ↓Regulatory scrutiny on Medicare billing and reimbursement changes pose operational risks.
  • ↓Adverse book-to-price dynamics and volatile trading could pressure future valuations.

Investment themes with ALHC

Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-02-2026neutral

Transcript signals

Bull points

  • For the quarter ended March 2026, health plan membership of 284,800 increased 31% year over year, driven by strong execution on sales and retention.
  • Increase in membership supported revenue of $1.2 billion in the quarter, representing 33% growth year over year.
  • First quarter adjusted gross profit of $146 million represented an NBR of 88.2%, which reflects an improvement of approximately 20 basis points year over year.

Bear points

  • candidly, I don't think we've cracked that code quite yet.
  • timing in the first quarter that might sort of reverse out in the rest of the year? Should we maybe expect that level of performance to kind of carry through the back half of the year?
  • It was a workflow problem, and we, of course, corrected it, but it impacted our January numbers, a couple million dollars, I think it was.
Read full transcript analysis ›